Gene Therapy On Cardiovascular Disease Market

Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.

Although several conventional small-molecule treatments are available for common cardiovascular problems, gene therapy is a potential treatment option for acquired and inherited cardiovascular diseases that remain with unmet clinical needs.

Gene Therapy On Cardiovascular Disease Market contains market size and forecasts of Gene Therapy On Cardiovascular Disease in Global, including the following market information:

Global Gene Therapy On Cardiovascular Disease Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Gene Therapy On Cardiovascular Disease market was valued at 13 million in 2021 and is projected to reach US$ 1073.1 million by 2028, at a CAGR of 87.1% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Viral Gene Therapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Gene Therapy On Cardiovascular Disease include Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals, Amgen, Spark Therapeutics, Akcea Therapeutics and bluebird bio, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Gene Therapy On Cardiovascular Disease companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Gene Therapy On Cardiovascular Disease Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Gene Therapy On Cardiovascular Disease Market Segment Percentages, by Type, 2021 (%)

• Viral Gene Therapy
• Non-Viral Gene Therapy

Global Gene Therapy On Cardiovascular Disease Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Gene Therapy On Cardiovascular Disease Market Segment Percentages, by Application, 2021 (%)

• Heart Disease
• Vascular Disease

Global Gene Therapy On Cardiovascular Disease Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Gene Therapy On Cardiovascular Disease Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Gene Therapy On Cardiovascular Disease revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies Gene Therapy On Cardiovascular Disease revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Biogen
• Novartis
• Gilead Sciences
• Sarepta Therapeutics
• Alnylam Pharmaceuticals
• Amgen
• Spark Therapeutics
• Akcea Therapeutics
• bluebird bio
• Sunway Biotech
• SIBIONO
• AnGes
• Orchard Therapeutics
• Human Stem Cells Institute